Interactions hôte-greffon, tumeur et ingénierie cellulaire et génique

The UMR1098 research unit, called “Host-graft-tumor interactions/Cell and gene engineering”, studies the interactions between the host immune system and a graft or a tumor. Recently, we have started to investigate also the dysregulation of the immune system during immune-mediated inflammatory diseases. A better understanding of the role of the immune system in these pathological situations based on the identification of circulating biomarkers will lead to the development of new innovative therapeutic approaches. This represents the two main goals of the research unit, namely: 1) to identify new biomarkers showing immune system dysregulation, and 2) to develop innovative therapies. These innovative therapies consist in cell-based therapies (now called advanced therapy medicinal products), gene-modified T cells (including CAR-T cells), biological skin substitutes, but also biological drugs, and a cancer vaccine. Since the research unit is hosted by the French national blood service (Etablissement Français du Sang [EFS]), we also study the interactions between the immune system and blood products. Moreover, the UMR1098 unit benefits from the capacity of EFS to produce advanced therapy medicinal products according to the European regulations.